Researchers classified cystic fibrosis-affected and healthy lung cells into different subtypes based on their gene expression patterns and then used bioinformatics to aid cataloging and classification of the cells with a view to helping develop new therapeutics.
Researchers from Harvard created a deep learning algorithm to accurately predict the location of a patient's unknown primary tumor using histology slide images, which they hope will improve diagnosis and treatment in these complex cases.
Ginkgo has developed its Concentric platform to provide easy start-up and operation for any school seeking easy-to-use digital participant sign-up, data management, supplies, integration of follow-up testing regimes, and fully staffed support services.
The researchers used mRNA technology to code for Cas13a, which destroys parts of the RNA genetic code that viruses use to replicate in cells in the lungs. Using a guide strand, researchers can provide a map that basically tells the Cas13a protein where to attach to the viruses’ RNA and begin to destroy it.
U.K. research shows that the inflammatory bowel disease drug infliximab stops the body’s immune system from mounting a strong antibody response to the SARS-CoV-2 virus, which may result in these patients being more susceptible to prolonged or repeat cases of COVID-19 and could mean they also have a weaker response to vaccination.
Researchers at the Baylor College of Medicine report that they have found that microbes in the gut may contribute to certain symptoms associated with complex neurological disorders, which also suggests that microbe-inspired therapies may one day help to treat them.
The study's authors suggested their work could lead to a combination antiviral therapy for COVID-19, which could be especially helpful to unvaccinated people who become infected and to vaccinated people who experience waning immunity.
The first in a new drug class of phosphodiesterase‐4D allosteric inhibitors developed by Tetra Therapeutics is well tolerated and helps improve cognition in people with fragile X syndrome, show results from a Phase II trial.
The kit is designed for purification of circulating cfNDA and uses silica coated paramagnetic particles to purify cfDNA from less than 1 mL to greater than 10 mL of serum or plasma.
With the aid of the n-lorem Foundation, doctors and patients now have hope of finding treatments to the most rare of genetic diseases.
A wider reach—in patients and data—promises better outcomes.
Broader, more diverse genomic data sets allow better training of polygenic risk score algorithms, moving them from research models into the clinic.
This year we highlight a range of leaders in precision medicine ranging from infectious disease experts to CRISPR researchers to company founders.